DB05363ExperimentalSmall molecule
LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
- Mechanism
- Curator reviewed
The mechanisms by which the compounds of the invention exert their anticonvulsant effects are not completely understood, but their activity may be partly due to effects on ion flow across neuronal membranes.
- Primary indication
- Investigated for use/treatment in bipolar disorders.Curator reviewed
- Code names
- LIC-477
Which companies are running trials of LIC-477, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account